Metraipolis › archive › dc_179b0ac2a641

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer — Europe PMC PMID:39676240

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/39676240
DOI
10.1002/cam4.70226
License (as archived)
solo-consultazione
Archived
2026-10-08T00:24:00.250Z
SHA-256 of the archived text
c0501fc429c5d6857383750b8b5f76e3c2b9783e4095bdf83438a45fe2116930
Stable URL of this page
https://metraipolis.com/documento/dc_179b0ac2a641

How to cite

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer — Europe PMC PMID:39676240 — Europe PMC (en), https://europepmc.org/article/MED/39676240 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_179b0ac2a641 (Metraipolis archive dc_179b0ac2a641, sha256 c0501fc429c5d6857383750b8b5f76e3c2b9783e4095bdf83438a45fe2116930)
BibTeX
@misc{dc179b0ac2a641,
  title = {Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer — Europe PMC PMID:39676240},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39676240},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_179b0ac2a641; sha256 c0501fc429c5d6857383750b8b5f76e3c2b9783e4095bdf83438a45fe2116930},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/39676240. Agents can read the archived copy with the MCP tool read_document.